TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

August 1, 2024

Study Completion Date

October 1, 2024

Conditions
Living Donor Kidney Transplantation
Interventions
BIOLOGICAL

Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs

Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of \>10 x10\^6 cells /Kg, 100 x 10\^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10\^6/Kg.

Trial Locations (2)

60611

RECRUITING

Nothwestern University, Chicago

94305

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

Northwestern University

OTHER

lead

Stanford University

OTHER